ESR1 mutations are common in people with ER+/HER2- metastatic breast cancer and may be acquired after treatment with certain hormone therapies. Watch this short video to learn more about ESR1 mutations. They may impact which treatment is most appropriate for you.
Dr VK Gadi discusses how, when, and why your ER+/HER2- metastatic breast cancer may develop ESR1 mutations. He explains why it’s important to understand your test results so you can have informed and proactive discussions with your doctor.